Copyright
©The Author(s) 2021.
World J Clin Oncol. Oct 24, 2021; 12(10): 882-896
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.882
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.882
Figure 1 Lenalidomide mechanisms of action.
IL: Interleukin; VEGF: Vascular endothelial growth factor.
- Citation: Cencini E, Fabbri A, Mecacci B, Bocchia M. Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas. World J Clin Oncol 2021; 12(10): 882-896
- URL: https://www.wjgnet.com/2218-4333/full/v12/i10/882.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i10.882